Accepts GoM's final recommendations without changes, say sources

The Cabinet today endorsed the recommendations of a Group of Ministers’ (GoM) on a revised National Pharmaceutical Pricing Policy, giving shape to a long-pending issue. The government did not give out details of the decision. According to sources, the Cabinet has imposed a cap on prices of 348 essential medicines at the arithmetic average of prices of all drugs in a particular segment with more than one per cent market share, in line with the GoM’s new recommendations.

The Central Government on Wednesday said it had resolved all issues concerning the drug pricing policy and would finalise its stand before November 27, the deadline set by the Supreme Court.

A Group of Ministers (GoM) headed by Agriculture Minister Sharad Pawar on Wednesday met to discuss the issues. “We have resolved all the issues. There were certain issues that were raised by my colleagues. We discussed them in depth and we have come to an agreed formula...I think we will be able to take Cabinet’s approval before November 27,” Mr. Pawar told reporters here after the meeting.

Chidambaram to be special invitee at Friday?s review meeting SC wants clear policy by November 27 hearing

The long-pending pharmaceutical pricing policy revamp, awaiting Cabinet approval, has been sent back to the group of ministers (GoM) which finalised it. The prime minister’s office (PMO) wants the GoM to address concerns raised by the finance ministry. Finance Minister P Chidambaram, not part of this GoM, would be a “special invitee” to the panel’s meeting scheduled for Friday. The GoM is headed by Agriculture Minister Sharad Pawar.

New Delhi In a big relief to generic drug major Cipla, the Supreme Court has stayed the Delhi High Court’s order that restrained the Indian company from marketing generic version of its anti-cancer drug Sunitinib, which is being developed by US pharmaceutical firms Sugen and Pharmacia & Upjohn Company.

The Indian drug major had sought permission from the apex court to market the drug in view of the revocation of patent rights by Intellectual Property Appellate Board (IPAB) to Sugen.

In a big relief to generic drug major Cipla, the Supreme Court has stayed the Delhi High Court’s order that restrained the Indian company from marketing generic version of its anti-cancer drug Suni

LUCKNOW: Central Drug Research Institute, Lucknow has developed a drug - 'Novel Bone Anabolic Agents' for accelerated healing of fractures by stimulating bone formation.

The increasing demand of the herbal industry for ‘naag chhatri’, a perennial medicinal plant found in the temperate zone of the Himalayas, is leading to its indiscriminate and excessive exploitatio

New Delhi: The ban on doctors, being sponsored by pharma firms to attend conferences, could soon get diluted.